Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024)

Artiva Biotherapeutics (ARTV) posted quarterly EBITDA Margin of 5773.71% for Q1 2024, down 1033.52% quarter-over-quarter from 509.36% in Q4 2023.

Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported EBITDA Margin for 2 consecutive years, with 5773.71% the latest figure, recorded in Q1 2024.

In Q1 2024, EBITDA Margin changed N/A year-over-year to 5773.71%; the TTM figure through Dec 2024 stood at 26806.37% (changed N/A YoY), while the FY2024 annual figure was 26805.58%, down 2671400.0% from the prior year.
EBITDA Margin slipped to 5773.71% in Q1 2024 per ARTV's latest filing, from 509.36% in the prior quarter.
Across five years, EBITDA Margin topped out at 40.56% in Q3 2023 and bottomed at 5773.71% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Artiva Biotherapeutics	451.28 Mn	451.28 Mn	-	-

Download Data